New research indicates GLP1-RA medications do not increase thyroid cancer risk, reassuring users and clinicians. A new study, ...

Being overweight raises your risk of thyroid cancer ... One study reported that the incidence of thyroid cancer in semaglutide-treated patients was less than 1%. As of now, the FDA warning ...

Researchers from the University of Bern analyzed over 300,000 FDA reports and found semaglutide use was linked to a higher ...

The following text highlights some of these precautions. Boxed warning: Risk of thyroid cancer Semaglutide (the active ingredient in Ozempic and Wegovy) has a boxed warning for a possible risk of ...

Ozempic (semaglutide) and Mounjaro (tirzepatide ... doctor to see if these warnings apply to you. Boxed warning: Risk of thyroid cancer Ozempic and Mounjaro both have a boxed warning for the ...

A new analysis of FDA adverse event reports suggests a potential link between tirzepatide and thyroid cancer. Learn what this ...

Animal studies have shown that using liraglutide (the active ingredient in Saxenda) or semaglutide (the active ingredient in Ozempic) may increase the risk of thyroid cancer. However, the risk of ...

For patients with diabetes, semaglutide use is associated with an increased risk for nonarteritic anterior ischemic optic ...

Ozempic and similar semaglutide-based medications have been ... Rarely, serious side effects such as pancreatitis and thyroid cancer can occur. "It's too early to know whether using GLP-1s to ...

Researchers suggest the 20% reduction in nonfatal heart attacks was the primary driver of this benefit for patients with type ...

The use of semaglutide in patients with diabetes was associated with a significantly increased risk for nonarteritic anterior ischemic optic neuropathy (NAION) compared with those taking drugs for ...